India Extends Grants To Drug Makers For Neglected Diseases
This article was originally published in PharmAsia News
A Cabinet committee of the Indian government approved a provision to extend grants to drug makers to encourage development of drugs for neglected diseases. The grants would include research for treatments for malaria, tuberculosis, kala-azar, filariasis and other diseases pharma companies are generally not developing, but which are considered a threat in tropical India. Under the current plan that would be extended by the Cabinet Committee on Economic Affairs, drug makers would be eligible for soft loans for up to 70 percent of the total project cost at 3 percent interest for 10 years. (Click here for more
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 24 November.
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.